NewcelX Ltd. (NCEL) Financials
Ticker history: NLSP became NCEL (NewcelX Ltd.) on . Earlier news and filings retain their original names and dates. View NLSP history.
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Apr 29, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NCEL SEC filings page.
This page shows NewcelX Ltd. (NCEL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (20-F and 6-K reports).
NewcelX remains loss-making with cash needs driven mainly by operations, while its FY2025 balance sheet improved but stayed short-term tight.
The FY2025 net loss was$8.3M , far larger than operating cash outflow of$2.8M , so reported earnings included costs that did not immediately consume cash. Because free cash flow was only slightly below operating cash flow, with capital expenditures of just$8K , the cash gap reflects earnings quality more than heavy reinvestment.
Equity moved from negative
FY2025 current ratio was 0.8x, below 1.0x, so near-term obligations still exceeded current assets. Financing cash flow of
Financial Health Signals
We do not publish a peer-relative financial health score for NewcelX Ltd., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
NewcelX Ltd. passes 2 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 3 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
NewcelX Ltd. reported a net loss of $8.3M while operations used $2.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
NewcelX Ltd.'s EBITDA was -$2.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior year is not meaningful, because that figure was zero or negative.
NewcelX Ltd. reported a net loss of $8.3M in fiscal year 2025.
NewcelX Ltd. earned $2.16 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 11.1% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
NewcelX Ltd. recorded an outflow of $2.8M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.
NewcelX Ltd. held $2.2M in cash as of fiscal year 2025; no long-term debt figure is on record for that period.
Not reported for fiscal year 2025.
Margins & Returns
NewcelX Ltd.'s ROE was -114.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
NewcelX Ltd. invested $1.1M in research and development in fiscal year 2025. This represents an increase of 13.5% from the prior year.
NewcelX Ltd. invested $8K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 33.3% from the prior year.
Not reported for fiscal year 2025.
NCEL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $1.1M+13.5% | $992K-38.3% | $1.6M-82.1% | $9.0M+51.6% | $5.9M+5844.4% | $100K-88.9% | $898K+26.7% | $708K |
| SG&A Expenses | $1.3M+67.5% | $805K-42.8% | $1.4M-78.4% | $6.5M+9.5% | $5.9M+170.1% | $2.2M-33.3% | $3.3M+20.4% | $2.7M |
| Operating Income | -$2.6Mn/m | -$2.1Mn/m | -$3.0Mn/m | -$15.5Mn/m | -$11.9Mn/m | -$2.3M | N/A | -$3.4M |
| EBITDA | -$2.5Mn/m | -$1.7Mn/m | -$2.4Mn/m | -$15.5Mn/m | -$11.9M | N/A | N/A | N/A |
| Interest Expense | N/A | $45K-62.4% | $120K+26.0% | $95K+97.9% | $48K-44.6% | $87K+8649.2% | $992 | N/A |
| Net Income | -$8.3M | N/A | -$3.3Mn/m | -$16.5Mn/m | -$11.9Mn/m | -$2.9M | N/A | -$5.1M |
| EPS (Basic) | $2.16-11.1% | $2.43 | $1.13 | -$33.52 | -$1.00 | -$0.41 | N/A | N/A |
| EPS (Diluted) | $2.16-11.1% | $2.43 | $1.13 | -$33.52 | -$1.00 | -$0.41 | N/A | N/A |
| Diluted Shares (Avg) | 4M+29.9% | 3M | 3M | 492,066 | 12M | 7M | N/A | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
NCEL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $11.4M+1167.4% | $903K-51.1% | $1.8M-80.1% | $9.3M+60.9% | $5.8M+375.8% | $1.2M+74.0% | $696K | N/A |
| Current Assets | $3.2M+307.9% | $780K-57.2% | $1.8M-80.3% | $9.2M+61.6% | $5.7M+2809.4% | $197K-48.5% | $382K | N/A |
| Cash & Equivalents | $2.2M+238.6% | $650K-43.3% | $1.1M-87.2% | $8.9M+64.8% | $5.4M+5695.7% | $94K-57.5% | $220K+3198.4% | $7K |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 |
| Goodwill | $1.7M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $4.2M-52.9% | $8.9M+192.4% | $3.0M-66.8% | $9.2M+75.5% | $5.2M-48.8% | $10.2M+48.5% | $6.9M | N/A |
| Current Liabilities | $4.2M-52.9% | $8.9M | N/A | $3.4M+39.8% | $2.4M-66.6% | $7.2M+78.5% | $4.0M | N/A |
| Non-Current Liabilities | $0n/m | $0 | N/A | $5.8M+106.0% | $2.8M-5.8% | $3.0M+5.6% | $2.8M | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | $113K | N/A | N/A |
| Total Equity | $7.3Mn/m | -$8.0Mn/m | -$1.2M-1178.4% | $111K-79.5% | $542Kn/m | -$9.0Mn/m | -$6.2Mn/m | -$8.8M |
| Retained Earnings | -$84.9Mn/m | -$76.6Mn/m | -$70.4Mn/m | -$58.2Mn/m | -$41.7Mn/m | -$29.8Mn/m | -$26.9M | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable.
NCEL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.8Mn/m | -$1.1Mn/m | -$3.4Mn/m | -$13.9Mn/m | -$14.9Mn/m | -$729Kn/m | -$190Kn/m | -$2.7M |
| Depreciation & Amortization | $55K-86.7% | $413K-33.4% | $620K+5334.8% | $11K+13.5% | $10K | N/A | N/A | N/A |
| Stock-Based Compensation | $765K+267.8% | $208K+39.6% | $149K+555.5% | $23K | N/A | N/A | N/A | N/A |
| Capital Expenditures | $8K+33.3% | $6K0.0% | $6K | N/A | $40K | N/A | N/A | N/A |
| Free Cash Flow | -$2.8Mn/m | -$1.1Mn/m | -$3.5M | N/A | -$15.0M | N/A | N/A | N/A |
| Investing Cash Flow | $1.7Mn/m | -$6K-105.8% | $103K | N/A | -$40K | N/A | N/A | N/A |
| Financing Cash Flow | $2.6M+484.2% | $450K-84.2% | $2.8M-83.6% | $17.4M-14.5% | $20.3M+3939.1% | $504K+23.6% | $407K-27.0% | $558K |
| Dividends Paid | N/A | $2.1M | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Share Buybacks.
NCEL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -114.5% | N/A | N/A | -14861.0%-12658.5pp | -2202.5% | N/A | N/A | N/A |
| Return on Assets | -72.5% | N/A | -180.4%-2.6pp | -177.8%+29.4pp | -207.2%+28.9pp | -236.2% | N/A | N/A |
| Current Ratio | 0.76+0.7x | 0.09 | N/A | 2.75+0.4x | 2.38+2.4x | 0.03-0.1x | 0.09 | N/A |
| Liabilities-to-Equity | 0.58 | N/A | N/A | 82.57+72.9x | 9.63 | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.
Note: The current ratio is below 1.0 (0.76), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| NewcelX Ltd. NCEL | FY2025 | N/A | -$8.3M | N/A | $15.2M | — |
| Allarity Therapeutics, Inc. ALLR | FY2025 | $320K | -$11.2M | N/A | $18.0M | — |
| Dyadic International, Inc. DYAI | FY2025 | $3.1M | -$7.4M | N/A | $14.4M | 51/100 |
| Acumen Pharmaceuticals, Inc. ABOS | FY2025 | N/A | -$121.3M | N/A | $17.0M | — |
| Karyopharm Therapeutics Inc. KPTI | FY2025 | $146.1M | -$196.0M | N/A | $2.0M | 47/100 |
| Dare Bioscience, Inc. DARE | FY2025 | $1.0M | -$13.4M | N/A | $12.8M | 55/100 |
Where NewcelX Ltd. Ranks
Frequently Asked Questions
No, NewcelX Ltd. (NCEL) reported a net loss of $8.3M in fiscal year 2025.
NewcelX Ltd. (NCEL) had EBITDA of -$2.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
NewcelX Ltd. (NCEL) has a return on equity of -114.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
NewcelX Ltd. (NCEL) recorded an outflow of $2.8M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
NewcelX Ltd. (NCEL) recorded an outflow of $2.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
NewcelX Ltd. (NCEL) had $11.4M in total assets as of fiscal year 2025, including both current and long-term assets.
NewcelX Ltd. (NCEL) invested $8K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
NewcelX Ltd. (NCEL) invested $1.1M in research and development during fiscal year 2025.
NewcelX Ltd. (NCEL) had a current ratio of 0.76 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
NewcelX Ltd. (NCEL) had a liabilities-to-equity ratio of 0.58 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
NewcelX Ltd. (NCEL) had a return on assets of -72.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
NewcelX Ltd. (NCEL) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $15.2M as of Nov 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
NewcelX Ltd. (NCEL) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $15.2M as of Nov 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, NewcelX Ltd. (NCEL) held $2.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $2.8M over that year. Dividing the one by the other, the reported balance equals about 10 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
NewcelX Ltd. (NCEL) has a Piotroski F-Score of 2 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
NewcelX Ltd. (NCEL) reported a net loss of $8.3M while operations used $2.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.